Carlos Alvarez

RN,MD,MSc - MedOnc @HUCA_asturias #ISPA Opiniones propias. Siempre compartiendo, dialogando y aprendiendo. #ShareKnowledge #InGodWeTrustAllOthersBringData

[Carlos Alvarez @duemed]

Publicados los resultados del TALAPRO-3 en el que el @HUCA_Asturias @astursalud ha participado activamente evaluando el estado mutacional de genes HRR de numerosos pacientes con CPHSm y gracias a ello varios pacientes ha podido beneficiarse de este estudio que ha sido positivo.

[NEJM @NEJM]

Original Article: PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer (phase 3 TALAPRO-3 trial) https://t.co/NIEgLZ9cPR

Editorial: Precision Intensification in Metastatic Prostate Cancer https://t.co/BWxAVFh2ZM

#ASCO26 | @ASCO

[Carlos Alvarez @duemed]

@tompowles1 @neerajaiims @OncoAlert The only information from supplemmentary appendix in the @NEJM paper on non-BRCA HRR population is this 👇

It seems ATM should not be left aside 🤔
#ASCO26

[Carlos Alvarez @duemed]

Dr Paolo Bossi in Oviedo, during the IV IUOPA International Symposium

https://t.co/7mE7DsWvzx

[Carlos Alvarez @duemed]

@ArchiOviedo se nos queda pequeña la iglesia, pero no la fe
#Pascua2026 #domingodeRamos2026 #parroquiaCovadongaOviedo

[Carlos Alvarez @duemed]

#GU26 K-COMPASS model

[Carlos Alvarez @duemed]

#GU26 KIM-1 and ctDNA as prognostic marker in oligometastatic ccRCC: K-COMPASS model
by @ChadTangMD

[Carlos Alvarez @duemed]

#GU26 K-COMPASS model

[Carlos Alvarez @duemed]

#GU26

[Carlos Alvarez @duemed]

LITESPARK-024, a phase 1/2 ascending dose escalation of belzutifan plus palbo for treated advanced ccRCC, presented by Dr McDermott from @BIDMChealth

[Carlos Alvarez @duemed]

#GU26

[Carlos Alvarez @duemed]

#GU26 Cabozantinib in pts with relapsed refractory GCTs presented by @JenniferKingMD

[Carlos Alvarez @duemed]

#GU26

[Carlos Alvarez @duemed]

#GU26 Closing remarks from discussion by @katy_beckermann

[Carlos Alvarez @duemed]

Great discussion of LITESPARK-022 trial by @katy_beckermann #GU26

[Carlos Alvarez @duemed]

#GU26 Discussion of LITESPARK-011 trial

[Carlos Alvarez @duemed]

#GU26 PROs outcomes in resected RCC – RAMPART study

[Carlos Alvarez @duemed]

PROs outcomes in resected RCC – RAMPART study
#GU26

[Carlos Alvarez @duemed]

#GU26 PROs outcomes in resected RCC – RAMPART study

[Carlos Alvarez @duemed]

#GU26 LITESPARK-022

[Carlos Alvarez @duemed]

LITESPARK-022: adjuvant pembrolizumab plus belzutifan vs pembrolizumab for ccRCC #GU26
@DrChoueiri @motzermd @crisuarez08 @DrIacovelli @tompowles1 @DrYukselUrun

[Carlos Alvarez @duemed]

#GU26 LITESPARK-022